newsfilter
← Latest News
PR Newswire·

Azitra, Inc. Addresses False Report Regarding Sale of Securities

  • Azitra, Inc. issued a statement on Nov. 7, 2025, denying a false report claiming the company priced a $44 million registered direct offering.
  • The company urged investors to rely only on information from official channels & stated it is identifying the source of the misinformation.
  • Azitra is a clinical stage biopharmaceutical company developing precision dermatology therapies using engineered strains of S. epidermidis.
  • Lead program ATR-12 treats Netherton syndrome & is currently in a Phase 1b clinical trial for adult patients.
  • Advanced program ATR-04 targets EGFR inhibitor-associated rash, has received FDA Fast Track designation, & has an open IND.
  • Preclinical program ATR-01 targets ichthyosis vulgaris with a goal to submit an IND in 2026.
  • The company's proprietary platform utilizes a microbial library of approximately 1,500 bacterial strains augmented by AI & machine learning.